Review Period Set for Pfizer’s Apoquel

Federal Register Notice: FDA has determined the regulatory review period for Pfizer’s Apoquel (oclacitinib) for extending a patent which claims the animal drug product. Apoquel is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. To view this notice, click here.

Read more